Cargill Set To Re-open On Monday

May 04, 2020

Cargill is looking at re-opening its meat packing plant in High River on Monday.

Jon Nash, Cargill’s North America Protein Lead says in partnership with health, regulatory officials and after taking actions suggested by the local union, we have made the decision to reopen our facility in High River, following a 14-day idle.

The company says all employees who are eligible to return to work in the harvest department are asked to report to work.

The reopening will see the processing facility running a single shift daily following a two-week temporary shutdown.

The company has been working with Alberta Health Services on a number of safety measures to help prevent the further spread of COVID 19.

Cargill has been connected with one of the largest COVID-19 outbreaks with more than 800 of its 2000 employees being infected.

In a statement the company says it has put in place a number of safety protocols from transportation to reassigning lockers, adding additional barriers, and increasing sanitation methods.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.